Methods and compositions related to clot binding compounds
View Patent ↗Disclosed are compositions and methods related to clot binding compounds. For example, disclosed are conjugates comprising a surface molecule and a plurality of clot binding compounds. The clot binding compounds can selectively bind to clotted plasma protein. The conjugate can, for example, cause clotting and amplify the accumulation of the conjugate in tumors. In one example, the conjugate can comprise a sufficient number and composition of clot binding compounds such that the conjugate causes clotting and amplifies the accumulation of the conjugate in tumors. The disclosed targeting is useful for treatment of cancer and other diseases and disorders.
1. A conjugate comprising a surface molecule and a plurality of clot binding compounds conjugated to the surface molecule, wherein the clot binding compounds selectively bind to clotted plasma protein, wherein the conjugate causes clotting and amplifies the accumulation of the conjugate in tumors, wherein some of the plurality of the clot binding compounds each independently comprise an amino acid segment comprising the amino acid sequence REK, wherein the surface molecule is an iron oxide nanoparticle.
2. The conjugate of claim 1 , wherein all of the plurality of clot binding compounds each independently comprise an amino acid segment comprising the amino acid sequence REK.
3. The conjugate of claim 1 , wherein the amino acid segments each independently comprise the amino acid sequence CREKA (SEQ ID NO: 1).
4. The conjugate of claim 3 , wherein the amino acid segment consists of the amino acid sequence CREKA (SEQ ID NO: 1).
5. The conjugate of claim 1 , wherein sufficiency of the density and composition of clot binding compounds is determined by assessing clotting and amplification of the accumulation of the conjugate in tumors in a non-human animal.
6. The conjugate of claim 1 , wherein some of the plurality of clot binding compounds are each independently selected from an amino acid segment comprising a fibrin-binding peptide, a clot binding antibody, and a clot binding small organic molecule.
7. The conjugate of claim 1 , wherein the amino acid segments are each independently selected from amino acid segments comprising the amino acid sequence CREKA (SEQ ID NO: 1), amino acid segments consisting of the amino acid sequence CREKA (SEQ ID NO: 1), and amino acid segments consisting of the amino acid sequence REK.
8. The conjugate of claim 1 , wherein the amino acid segment consists of the amino acid sequence CREKA (SEQ ID NO: 1).
9. The conjugate of claim 1 , wherein some of the plurality of clot binding compounds each comprise a fibrin-binding peptide.
10. The conjugate of claim 9 , wherein the fibrin-binding peptides are independently selected from the group consisting of fibrin binding peptides and fibrin-binding derivatives thereof.
11. The conjugate of claim 1 , wherein the conjugate comprises at least 100 clot binding compounds.
12. The conjugate of claim 1 , wherein the conjugate comprises at least 1000 clot binding compounds.
13. The conjugate of claim 1 , wherein the conjugate comprises at least 1200 clot binding compounds.
14. The conjugate of claim 1 , wherein the conjugate comprises at least 1500 clot binding compounds.
15. The conjugate of claim 1 , wherein the conjugate comprises at least 2000 clot binding compounds.
16. The conjugate of claim 1 , wherein the conjugate comprises at least 10,000 clot binding compounds.
17. The conjugate of claim 1 , wherein conjugate further comprises one or more moieties, each of the one or more moieties being independently selected from the group consisting of an anti-angiogenic agent, a pro-angiogenic agent, a cancer chemotherapeutic agent, a cytotoxic agent, an anti-inflammatory agent, an anti-arthritic agent, a polypeptide, a nucleic acid molecule, a small molecule, a detectable agent, a fluorophore, fluorescein, rhodamine, a radionuclide, indium-111, technetium-99, carbon-11, and carbon-13.
18. The conjugate of claim 17 , wherein at least one of the moieties is a therapeutic agent.
19. The conjugate of claim 18 , wherein the therapeutic agent is paclitaxel.
20. The conjugate of claim 18 , wherein the therapeutic agent is taxol.
21. The conjugate of claims 17 , wherein at least one of the moieties is a detectable agent.
22. The conjugate of claim 1 , wherein the conjugate selectively homes to clotted plasma protein.
23. The conjugate of claim 1 , wherein the conjugate selectively homes to tumor vasculature, wound sites, or both.
24. The conjugate of claim 1 , wherein clotted plasma protein comprises fibrin.
25. A conjugate comprising a surface molecule and a plurality of clot binding compounds conjugated to the surface molecule, wherein the clot binding compounds selectively bind to clotted plasma protein, wherein the conjugate causes clotting and amplifies the accumulation of the conjugate in tumors, wherein some of the plurality of the clot binding compounds each independently comprise an amino acid segment comprising the amino acid sequence CREKA (SEQ ID NO: 1), wherein the surface molecule is an iron oxide nanoparticle.
26. The conjugate of claim 25 , wherein all of the plurality of clot binding compounds each independently comprise an amino acid segment comprising the amino acid sequence REK.
27. The conjugate of claim 25 , wherein the amino acid segments each independently comprise the amino acid sequence CREKA (SEQ ID NO: 1).
28. The conjugate of claim 27 , wherein the amino acid segment consists of the amino acid sequence CREKA (SEQ ID NO: 1).
29. The conjugate of claim 25 , wherein sufficiency of the density and composition of clot binding compounds is determined by assessing clotting and amplification of the accumulation of the conjugate in tumors in a non-human animal.
30. The conjugate of claim 25 , wherein some of the plurality of clot binding compounds are each independently selected from an amino acid segment comprising a fibrin-binding peptide, a clot binding antibody, and a clot binding small organic molecule.
31. The conjugate of claim 25 , wherein the amino acid segments are each independently selected from amino acid segments comprising the amino acid sequence CREKA (SEQ ID NO: 1), amino acid segments consisting of the amino acid sequence CREKA (SEQ ID NO: 1), and amino acid segments consisting of the amino acid sequence REK.
32. The conjugate of claim 25 , wherein the amino acid segment consists of the amino acid sequence CREKA (SEQ ID NO: 1).
33. The conjugate of claim 25 , wherein some of the plurality of clot binding compounds each comprise a fibrin-binding peptide.
34. The conjugate of claim 33 , wherein the fibrin-binding peptides are independently selected from the group consisting of fibrin binding peptides and fibrin-binding derivatives thereof.
35. The conjugate of claim 25 , wherein the conjugate comprises at least 100 clot binding compounds.
36. The conjugate of claim 25 , wherein the conjugate comprises at least 1000 clot binding compounds.
37. The conjugate of claim 25 , wherein the conjugate comprises at least 1200 clot binding compounds.
38. The conjugate of claim 25 , wherein the conjugate comprises at least 1500 clot binding compounds.
39. The conjugate of claim 25 , wherein the conjugate comprises at least 2000 clot binding compounds.
40. The conjugate of claim 25 , wherein the conjugate comprises at least 10,000 clot binding compounds.
41. The conjugate of claim 25 , wherein conjugate further comprises one or more moieties, each of the one or more moieties being independently selected from the group consisting of an anti-angiogenic agent, a pro-angiogenic agent, a cancer chemotherapeutic agent, a cytotoxic agent, an anti-inflammatory agent, an anti-arthritic agent, a polypeptide, a nucleic acid molecule, a small molecule, a detectable agent, a fluorophore, fluorescein, rhodamine, a radionuclide, indium-111, technetium-99, carbon-11, and carbon-13.
42. The conjugate of claim 41 , wherein at least one of the moieties is a therapeutic agent.
43. The conjugate of claim 42 , wherein the therapeutic agent is paclitaxel.
44. The conjugate of claim 42 , wherein the therapeutic agent is taxol.
45. The conjugate of claims 41 , wherein at least one of the moieties is a detectable agent.
46. The conjugate of claim 25 , wherein the conjugate selectively homes to clotted plasma protein.
47. The conjugate of claim 25 , wherein the conjugate selectively homes to tumor vasculature, wound sites, or both.
48. The conjugate of claim 25 , wherein clotted plasma protein comprises fibrin.